Trial Outcomes & Findings for Subjective Comfort With Multipurpose and Hydrogen Peroxide Lens Care Solutions in Soft Contact Lens Wearers (NCT NCT01164865)
NCT ID: NCT01164865
Last Updated: 2012-10-12
Results Overview
Ocular comfort was rated by the participant on a continuous visual analog scale from 0-100, where 0=extremely uncomfortable, 50=neither comfortable nor uncomfortable, and 100=extremely comfortable. The participant marked a horizontal line across the scale at the point that best described "how your eyes feel right now."
COMPLETED
NA
78 participants
Baseline (Day 0), 2 weeks
2012-10-12
Participant Flow
Participants were recruited from two US study centers.
Participant milestones
| Measure |
OPTI-FREE RepleniSH
OPTI-FREE RepleniSH multipurpose disinfecting solution used with study contact lenses on a daily basis for 2 weeks.
|
Clear Care
Clear Care contact lens care system used with study contact lenses on a daily basis for 2 weeks.
|
|---|---|---|
|
Overall Study
STARTED
|
39
|
39
|
|
Overall Study
COMPLETED
|
37
|
38
|
|
Overall Study
NOT COMPLETED
|
2
|
1
|
Reasons for withdrawal
| Measure |
OPTI-FREE RepleniSH
OPTI-FREE RepleniSH multipurpose disinfecting solution used with study contact lenses on a daily basis for 2 weeks.
|
Clear Care
Clear Care contact lens care system used with study contact lenses on a daily basis for 2 weeks.
|
|---|---|---|
|
Overall Study
Lost to Follow-up
|
2
|
1
|
Baseline Characteristics
Subjective Comfort With Multipurpose and Hydrogen Peroxide Lens Care Solutions in Soft Contact Lens Wearers
Baseline characteristics by cohort
| Measure |
OPTI-FREE RepleniSH
n=39 Participants
OPTI-FREE RepleniSH multipurpose disinfecting solution used with study contact lenses on a daily basis for 2 weeks.
|
Clear Care
n=39 Participants
Clear Care contact lens care system used with study contact lenses on a daily basis for 2 weeks.
|
Total
n=78 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age Continuous
|
37.1 years
STANDARD_DEVIATION 12.27 • n=5 Participants
|
41.5 years
STANDARD_DEVIATION 9.59 • n=7 Participants
|
39.3 years
STANDARD_DEVIATION 11.16 • n=5 Participants
|
|
Sex: Female, Male
Female
|
29 Participants
n=5 Participants
|
26 Participants
n=7 Participants
|
55 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
10 Participants
n=5 Participants
|
13 Participants
n=7 Participants
|
23 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
39 participants
n=5 Participants
|
39 participants
n=7 Participants
|
78 participants
n=5 Participants
|
PRIMARY outcome
Timeframe: Baseline (Day 0), 2 weeksPopulation: All participants who received regimen, satisfied the inclusion/exclusion criteria, and completed the 14-day treatment period, including completion of the Visit 2 evaluations.
Ocular comfort was rated by the participant on a continuous visual analog scale from 0-100, where 0=extremely uncomfortable, 50=neither comfortable nor uncomfortable, and 100=extremely comfortable. The participant marked a horizontal line across the scale at the point that best described "how your eyes feel right now."
Outcome measures
| Measure |
OPTI-FREE RepleniSH
n=37 Participants
OPTI-FREE RepleniSH multipurpose disinfecting solution used with study contact lenses on a daily basis for 2 weeks.
|
Clear Care
n=38 Participants
Clear Care contact lens care system used with study contact lenses on a daily basis for 2 weeks.
|
|---|---|---|
|
Change From Baseline in Ocular Comfort Rating at 2 Weeks
|
-8.20 Units on a scale
Interval -13.84 to -2.55
|
-7.14 Units on a scale
Interval -12.74 to -1.54
|
PRIMARY outcome
Timeframe: 2 weeksPopulation: All participants who received regimen, satisfied the inclusion/exclusion criteria, and completed the 14-day treatment period, including completion of the Visit 2 evaluations.
The Likert Questionnaire included 8 questions on selected comfort measures. All responses were recorded on a 5-point scale, where 1=Strongly Disagree, 2=Disagree, 3=Undecided, 4=Agree, and 5=Strongly Agree.
Outcome measures
| Measure |
OPTI-FREE RepleniSH
n=37 Participants
OPTI-FREE RepleniSH multipurpose disinfecting solution used with study contact lenses on a daily basis for 2 weeks.
|
Clear Care
n=38 Participants
Clear Care contact lens care system used with study contact lenses on a daily basis for 2 weeks.
|
|---|---|---|
|
Likert Questionnaire Scores at 2 Weeks
I can comfortably wear my lenses
|
4.20 Units on a scale
Interval 3.96 to 4.44
|
4.24 Units on a scale
Interval 4.0 to 4.48
|
|
Likert Questionnaire Scores at 2 Weeks
My lenses stay moist from morning to evening
|
3.60 Units on a scale
Interval 3.28 to 3.92
|
3.69 Units on a scale
Interval 3.37 to 4.01
|
|
Likert Questionnaire Scores at 2 Weeks
The solution I use feels gentle on my eyes
|
4.00 Units on a scale
Interval 3.75 to 4.25
|
3.66 Units on a scale
Interval 3.41 to 3.91
|
|
Likert Questionnaire Scores at 2 Weeks
My lenses feel fresh
|
3.79 Units on a scale
Interval 3.52 to 4.05
|
4.03 Units on a scale
Interval 3.77 to 4.29
|
|
Likert Questionnaire Scores at 2 Weeks
At the end of the day, my vision is clear
|
3.54 Units on a scale
Interval 3.2 to 3.88
|
3.86 Units on a scale
Interval 3.52 to 4.19
|
|
Likert Questionnaire Scores at 2 Weeks
When I put my lenses in, they feel comfortable
|
4.05 Units on a scale
Interval 3.78 to 4.33
|
4.03 Units on a scale
Interval 3.76 to 4.3
|
|
Likert Questionnaire Scores at 2 Weeks
I like the way this product feels during handling
|
4.09 Units on a scale
Interval 3.84 to 4.34
|
3.66 Units on a scale
Interval 3.42 to 3.91
|
|
Likert Questionnaire Scores at 2 Weeks
My lenses feel moist
|
3.84 Units on a scale
Interval 3.56 to 4.12
|
3.64 Units on a scale
Interval 3.36 to 3.92
|
Adverse Events
OPTI-FREE RepleniSH
Clear Care
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Jami Kern, Ph.D.
Alcon Global Medical Affairs
Results disclosure agreements
- Principal investigator is a sponsor employee Alcon reserves the right of prior review of any publication or presentation of information related to the study.
- Publication restrictions are in place
Restriction type: OTHER